Joseph Franses, MD, PhD, is a skilled oncologist who focuses on gastrointestinal cancers, primarily hepatocellular carcinoma and biliary tract cancers. Dr. Franses is an expert in diagnosing and treating cancer and is known for his compassionate and individualized approach to patient care, taking the time to truly understand each patient's unique needs and concerns.
Dr. Franses is dedicated to improving the lives of his patients through both medical care and ongoing support. He works closely with a team of specialists to develop comprehensive treatment plans that are tailored to each patient's specific situation.
In addition to his clinical work, Dr. Franses is a physician-scientist who is committed to staying at the forefront of advancements in cancer treatment and uses this knowledge to provide the best possible care to his patients. He is actively involved in research that is investigating the tumor microenvironment and mechanisms of metastasis, focusing on how these features lead to de novo and acquired therapeutic resistance in gastrointestinal cancers. Dr. Franses’ work has been published in peer-reviewed journals like Nature Communications, Cancer Discovery, Gastroenterology, Annals of Surgery and more.
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Sep; 23(9):403-418.
PMID: 40930144
Limitations of Radiographic Response Assessments of Systemic Therapy for Advanced Hepatocellular Carcinoma.
Limitations of Radiographic Response Assessments of Systemic Therapy for Advanced Hepatocellular Carcinoma. JCO Precis Oncol. 2025 Aug; 9:e2500551.
PMID: 40825168
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma.
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma. JCO Precis Oncol. 2025 Jul; 9:e2400934.
PMID: 40601895
Bridging Immune Evasion and Vascular Dynamics for Novel Therapeutic Frontiers in Hepatocellular Carcinoma.
Bridging Immune Evasion and Vascular Dynamics for Novel Therapeutic Frontiers in Hepatocellular Carcinoma. Cancers (Basel). 2025 May 31; 17(11).
PMID: 40507341
Single Cell Spatial Transcriptomic Profiling Identifies a LINE1 Associated Disarrayed Immune Microenvironment in Hepatocellular Carcinoma.
Single Cell Spatial Transcriptomic Profiling Identifies a LINE1 Associated Disarrayed Immune Microenvironment in Hepatocellular Carcinoma. bioRxiv. 2025 May 26.
PMID: 38105940
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma.
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma. JAMA Netw Open. 2025 02 03; 8(2):e2461735.
PMID: 39998829
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nat Commun. 2025 01 02; 16(1):32.
PMID: 39746954
How to Predict Recurrence After Resection of Hepatocellular Carcinoma.
How to Predict Recurrence After Resection of Hepatocellular Carcinoma. Anticancer Res. 2025 Jan; 45(1):189-199.
PMID: 39740812
HCC spatial transcriptomic profiling reveals significant and potentially targetable cancer-endothelial interactions.
HCC spatial transcriptomic profiling reveals significant and potentially targetable cancer-endothelial interactions. Hepatol Commun. 2024 10 01; 8(10).
PMID: 39330965
Targeted therapies in hepatocellular carcinoma: past, present, and future.
Targeted therapies in hepatocellular carcinoma: past, present, and future. Front Oncol. 2024; 14:1432423.
PMID: 39267840